Emma Parmee Explained

Emma Parmee
Nationality:British
Other Names:Emma Rachel Parmee
Occupation:scientist
Employer:Merck & Co.
Awards:Gordon E. Moore Medal (SCI)

Emma Parmee is a British chemist and research scientist who is a co-inventor of numerous drug patents. She was one of the leading researchers in the development of sitagliptin and was awarded a Thomas Alva Edison Patent Award in 2007 and the Society of Chemical Industry's Gordon E Moore Medal in 2009 for her contributions.[1]

Biography

Emma Rachel Parmee was born in the United Kingdom obtaining a BA and PhD at the University of Oxford in chemistry.[2] She completed her thesis in 1990[3] and was awarded a NATO post-doctoral fellowship. She moved to the United States to complete her post-doctoral work under Saturo Masamune at the Massachusetts Institute of Technology, studying catalysts of asymmetric synthesis for aldol reactions. She completed her post-doctoral research in 1992 and joined Merck & Co. that same year working at their research laboratory in Rahway, New Jersey.

In 2006, Parmee was one of the lead investigators in the discovery of the selective Dipeptidyl peptidase-4 inhibitor sitagliptin (marketed by Merck under the trade name Januvia). The drug is used to treat Type 2 Diabetes and provides glucose lowering benefits without the side effects of some of the previously available treatments.[4] Her involvement was recognised by the award of the Thomas Alva Edison Patent Award from the Research and Development Council of New Jersey,[5] the Prix Galien[6] for Endocrinology in 2007[7] and the receipt of the 2009 Gordon E Moore Medal from the Society of Chemical Industry.

In 2010, Parmee left the Rahway lab and moved to the facility at West Point, Pennsylvania, where she served as the site lead for chemical discovery until 2013. Her group developed a small molecule CGRP antagonist.[8] She was then promoted to Associate Vice-President and Head of Exploratory Chemistry . She also serves as the co-chair of the Early Discovery Council for Merck Research Laboratories. She has written more than forty papers which have appeared in peer-reviewed publications and has filed for over thirty US patents on her work.[9] Parmee lives with her husband, son, and daughter.

Selected works

External links

Notes and References

  1. Web site: Center for Oral History. Emma R. Parmee . .
  2. Web site: 12th Annual Maria Goeppert-Mayer Interdisciplinary Symposium. University of Zurich. 19 November 2015. Zurich, Switzerland. 2006.
  3. Web site: Synthesis of avermectins and milbemycins. British Library. 19 November 2015.
  4. Web site: Emma Parmee Gordon E Moore 2009 Medalist. Society of Chemical Industry. 19 November 2015. London, England. 2009.
  5. The Research & Development Council of New Jersey 2007 Thomas Alva Edison Patent Awards . Cosmetiscope . December 2007 . 13 . 10 . 10 . New York Society of Cosmetic Chemists . Mt. Freedom, New Jersey .
  6. Web site: 31st Annual Tribute to Women and Industry Awards Dinner. YWCA of Central New Jersey. 19 November 2015. Plainfield, New Jersey. 26 May 2010. https://web.archive.org/web/20160216124344/http://journals.eventjournal.com/view_custom.php?journal_id=205&id=18558. 16 February 2016. dead.
  7. Web site: Winners Sorted by Medical Field. Prix Galien. 19 November 2015. Neuilly sur Seine, France. 2015. https://web.archive.org/web/20151104120152/http://www.prixgalien.com/en/05/02/winners-sorted-by-medical-field.htm. 4 November 2015. dead.
  8. Emma Parmee, Vice President, Discovery Chemistry, Merck. Industry Matters Newsletter . 9 July 2020 . American Chemical Society. 26 March 2021.
  9. Web site: Dr. Emma R. Parmee. Harvard University. 19 November 2015. Boston, Massachusetts. 2015.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Emma Parmee".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.